BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/11/2025 7:47:40 AM | Browse: 307 | Download: 1262
Publication Name World Journal of Gastroenterology
Manuscript ID 109285
Country China
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Infectious Diseases
Manuscript Type Clinical Trials Study
Article Title Tenofovir amibufenamide in chronic hepatitis B: Lipid changes and 144-week safety with tenofovir disoproxil fumarate-to-tenofovir amibufenamide switch
Manuscript Source Unsolicited Manuscript
All Author List Zhi-Hao Zeng, Jin-Qing Liu, Min Zhang, Cai-Liang Qiu and Zhen-Yu Xu
ORCID
Author(s) ORCID Number
Min Zhang http://orcid.org/0000-0002-2363-0393
Zhen-Yu Xu http://orcid.org/0000-0002-5839-5741
Funding Agency and Grant Number
Funding Agency Grant Number
The Scientific Research Program of FuRong Laboratory No. 2023SK2108
Clinical Medical Research Center for Viral Hepatitis of Hunan Province No. 2023SK4009
Hunan Provincial Natural Science Foundation No. 2023JJ60440
Hunan Provincial Health Commission Research Program No. 202303088786
Corresponding Author Zhen-Yu Xu, PhD, Department of Infectious Diseases, The Second Xiangya Hospital, Central South University, No. 139 People’s Middle Road, Changsha 410011, Hunan Province, China. xuzhenyu@csu.edu.cn
Key Words Tenofovir amibufenamide; Hepatitis B virus; Lipid profile; Lipoprotein; Cholesterol
Core Tip This 144-week dual-phase study investigated the long-term lipid and safety profile of tenofovir amibufenamide (TMF) in chronic hepatitis B patients. Through a randomized, double-blind comparison with tenofovir disoproxil fumarate (TDF) followed by a TDF-to-TMF switch, the trial revealed comparable antiviral efficacy, improved renal and bone safety, and a moderate elevation in lipid levels with TMF that stabilized after switch therapy. These findings support TMF as a viable first-line and sequential therapy option in real-world chronic hepatitis B management.
Publish Date 2025-07-11 07:47
Citation

Zeng ZH, Liu JQ, Zhang M, Qiu CL, Xu ZY. Tenofovir amibufenamide in chronic hepatitis B: Lipid changes and 144-week safety with tenofovir disoproxil fumarate-to-tenofovir amibufenamide switch. World J Gastroenterol 2025; 31(26): 109285

URL https://www.wjgnet.com/1007-9327/full/v31/i26/109285.htm
DOI https://dx.doi.org/10.3748/wjg.v31.i26.109285
Full Article (PDF) WJG-31-109285-with-cover.pdf